|Bid||0.0000 x 1300|
|Ask||0.0000 x 2900|
|Day's Range||0.2030 - 0.2359|
|52 Week Range||0.2030 - 1,463.9301|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 8, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pernix Therapeutics Holdings, Inc. (PTX) (“Pernix” or the “Company”), a holding company that owns several subsidiaries, including specialty pharmaceutical companies, today announced that it has entered into an Asset Purchase Agreement with certain funds managed by Highbridge Capital Management, LLC (collectively “Highbridge”). The Agreement serves as an initial “stalking-horse bid” to acquire substantially all of the assets of the Company and its subsidiaries, including the rights to all branded and generic products (the “Products”), for approximately $75.6 million in the form of cash and credit bid consideration. Pernix has also initiated voluntary proceedings under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware to undertake its restructuring and sale process.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Pernix Therapeutics Holdings, Inc.Read More...
NEW YORK, NY / ACCESSWIRE / February 14, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Pernix Therapeutics Holdings, Inc., (PTX) Pernix is the parent company of Pernix Therapeutics, LLC, a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs, primarily for the U.S. market. During the third quarter, Contrave remained the leading prescription weight loss brand in the United States, and the company is currently exploring a number of initiatives to enhance the value of the brand globally. Pernix is extremely encouraged with the initial results from Contrave, which is the market-leading branded weight loss prescription drug.
John Sedor became the CEO of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) in 2016. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After Read More...
NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
The Morristown, New Jersey-based company said it had a loss of 89 cents per share. The pharmaceutical posted revenue of $37.2 million in the period. In the final minutes of trading on Thursday, the company's ...
MORRISTOWN, N.J., Nov. 08, 2018 -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today its financial results for the three and.
MORRISTOWN, N.J., Nov. 02, 2018 -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that the Company will report financial.
If you’re interested in Pernix Therapeutics Holdings Inc (NASDAQ:PTX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock Read More...